{"brief_title": "A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs", "brief_summary": "The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV drugs.", "detailed_description": "In this open-label, strategic study patients are evaluated at Weeks 0, 1, 2, 4, 8, 12 to Week 48 after being treated on one of the following regimens: Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Didanosine", "criteria": "Inclusion Criteria Patients must have: - Diagnosed asymptomatic HIV infection. - HIV-1 RNA greater than 500 copies/ml. - CD4+ T-cell count greater than 200/mm3. - Never received antiretroviral therapy. Exclusion Criteria Co-existing Condition: Excluded: Severe non-HIV-related disease. Patients with the following prior conditions are excluded: History of neuropathy. Prior Medication: Excluded: - Investigational drug within 1 month prior to study. - Immunomodulatory drug within 1 month prior to study. Prior Treatment: Excluded: - Radiation therapy within past month. - Chemotherapy within past month.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002407.xml"}